[Fat distribution anomalies and other metabolic disorders in patients under antiretroviral therapy].
Certain HIV-infected patients develop fat distribution anomalies 3 to 6 months after the introduction of antiretroviral therapy. Partial or generalized lipodystrophy can be observed, in the form of central obesity with accumulation of fat in the cervicoscapular, thoracic, abdominal or hip areas. The underlying mechanism remains unknown. METABOLISM DISORDERS: Elevated serum triglyceride, cholesterol, LDL-cholesterol, VLDL-cholesterol and glucose levels have been reported. Treatment of these metabolic anomalies remains a delicate challenge for patient management.
Baril
L
L
Service de Maladies Infectieuses et de Médecine Tropicale, Hôpital de la Pitié-Salpêtrière, Paris.
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000998:Antiviral Agents; D004041:Dietary Fats / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008297:Male; D012190:Retroviridae / Q000187:drug effects
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D004041:Dietary Fats